Revolution Medicines, Inc.
NASDAQ:RVMD
Overview | Financials
Company Name | Revolution Medicines, Inc. |
Symbol | RVMD |
Currency | USD |
Price | 43.84 |
Market Cap | 7,994,224,000 |
Dividend Yield | 0% |
52-week-range | 43.84 - 44.12 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark A. Goldsmith Ph.D. |
Website | https://www.revmed.com |
An error occurred while fetching data.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD